Drug intelligence / Profile preview

EDP1066

Development stage: Phase 1
Lead developer: Evelo Biosciences
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

EDP1066 is an investigational **orally administered monoclonal microbial** therapy from Evelo Biosciences being developed as an oral biologic for inflammatory disease. Public clinical-trial records describe it as a single-strain, non-genetically modified microbial product delivered in capsules and evaluated in a first-in-human Phase 1a/1b randomized, double-blind, placebo-controlled study in healthy volunteers and in patients with mild to moderate psoriasis and atopic dermatitis. Its intended pharmacology appears to be **immunomodulation via host-microbe interactions in the small intestine**, consistent with Evelo's monoclonal microbial platform, but the exact molecular target and target-level mechanism were not explicitly identified in the provided sources. The program was publicly associated with Evelo's inflammatory disease pipeline and manufacturing arrangements with Sacco for oral delivery of single-strain microbes.

Beyond the preview

Go deeper on EDP1066.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDP1066.

Explore the full profile